Yatong Zhu 朱雅童 Zhu

Ms. Yatong Zhu 朱雅童 Zhu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
嫚苏嫚 苏
嫚 苏
XLxianru liu
xianru liu
ZYZhao Yuru
Zhao Yuru
YZYatong Zhu 朱雅童 Zhu
Yatong Zhu 朱雅童 Zhu
MWMengqiu Wu
Mengqiu Wu
LWLin Wang
Lin Wang
Acute kidney injury (AKI) and chronic kidney disease (CKD) have become public health problems due to high morbidity and mortality. Currently, drugs recommended for patients with AKI or CKD are extremely limited, and candidates based on a new mechanism need to be explored. 84-B10 is a novel 3-phenylglutaric acid derivative that can activate the mitochondrial protease, Lon protease 1 (LONP1), and may protect against cisplatin-induced AKI and unilateral ureteral obstruction- or 5/6 nephrectomy [5/6Nx]-induced CKD model. Preclinical studies have shown that 84-B10 has a good therapeutic effect, low toxicity, and is a good prospect for further development. In the present study, the UHPLC-MS/MS method was first validated then applied to the pharmacokinetic study and tissue distribution of 84-B10 in rats. Physicochemical properties of 84-B10 were then acquired in silico. Based on these physicochemical and integral physiological parameters, a physiological based pharmacokinetic (PBPK) model was developed using the PK-Sim platform. The fitting accuracy was estimated with the obtained experimental data. Subsequently, the validated model was employed to predict the pharmacokinetic profiles in healthy and chronic kidney injury patients to evaluate potential clinical outcomes. Cmax in CKD patients was about 3250 ng/mL after a single dose of 84-B10 (0.41 mg/kg), and Cmax,ss was 1360 ng/mL after multiple doses. This study may serve in clinical dosage setting in the future.

31 July 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
QCQiufang Chen
Qiufang Chen
YZYatong Zhu 朱雅童 Zhu
Yatong Zhu 朱雅童 Zhu
LWLin Wang
Lin Wang
MZMin Zhao
Min Zhao
Background and objective: Ginkgolide J is an active ingredient extracted from Ginkgo biloba leaves and has potential therapeutic effects on Alzheimer’s disease and rheumatoid arthritis. However, its pharmacokinetic behavior remains unclear. As the efficacy of an active ingredient in natural products is significantly affected by its pharmacokinetic characteristics, the pharmacokinetics of Ginkgolide J needs to be elucidated. Materials and methods: A rapid and sensitive quantitative method for Ginkgolide J using ultra-high-performance liquid chromatography-tandem mass spectrometry was established and validated. This method was then applied to pharmacokinetic studies in rats after oral and intravenous administration of a Ginkgolide J solution. Results: The linear range was 2–1000 ng/mL, with a correlation coefficient higher than 0.999. The specificity, precision, accuracy, stability, matrix effect, and recovery rate of this method met the analytical requirements. The pharmacokinetic results showed that the time to maximum plasma concentration (t max ) and half-life (t 1/2 ) after oral administration of Ginkgolide J (10 mg/kg) were 1.50 h and 3.25 h, and t 1/2 after intravenous administration (2 mg/kg) was 1.96 h, respectively. The absolute bioavailability of Ginkgolide J was 8.67%. Compared with intravenous medication, the oral bioavailability of Ginkgolide J is very low; therefore, the development of Ginkgolide J as an intravenous injection is more suitable for clinical applications. Conclusion: In this study, we established a method for analyzing Ginkgolide J based on ultra-high-performance liquid chromatography tandem mass spectrometry and measured its pharmacokinetic behavior in rats. The results showed that the oral bioavailability of Ginkgolide J is very low, and intravenous administration may be necessary for drug development.